News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Study Status:

Open for enrollment

Contact Information:

(956) 362-2394

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this trial is to find out if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will live longer and have a better quality of life if they start treatment earlier.

Information: 

Principal Investigator
Dr. Jose Cruz
Co-PI
Edgar Lopez Pacheco
Sponsor
National Cancer Institute (NCI)
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram